Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | WEE1 | P30291 | 6/20 | 0.64 |
| ▸ | ALK | Q9UM73 | 6/20 | 0.64 |
| ▸ | PDGFRA | P16234 | 7/20 | 0.61 |
| ▸ | JAK2 | O60674 | 5/20 | 0.61 |
| ▸ | ROCK1 | Q13464 | 4/20 | 0.61 |
| ▸ | AURKA | O14965 | 3/20 | 0.61 |
| ▸ | DAPK3 | O43293 | 3/20 | 0.61 |
| ▸ | PRKD3 | O94806 | 3/20 | 0.61 |
| ▸ | MAP4K4 | O95819 | 3/20 | 0.61 |
| ▸ | PAK4 | O96013 | 3/20 | 0.61 |
| ▸ | LCK | P06239 | 3/20 | 0.61 |
| ▸ | FYN | P06241 | 3/20 | 0.61 |
| ▸ | CSF1R | P07333 | 3/20 | 0.61 |
| ▸ | RET | P07949 | 3/20 | 0.61 |
| ▸ | IGF1R | P08069 | 3/20 | 0.61 |
| ▸ | FGFR1 | P11362 | 3/20 | 0.61 |
| ▸ | PRKACA | P17612 | 3/20 | 0.61 |
| ▸ | FLT1 | P17948 | 3/20 | 0.61 |
| ▸ | LTK | P29376 | 3/20 | 0.61 |
| ▸ | KDR | P35968 | 3/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3771293 | 0.89 | WEE1 (0.62) | WEE1ALKPDGFRAJAK2ROCK1 | |
| SCHEMBL3767432 | 0.76 | ALK (1.00) | WEE1ALKPDGFRAJAK2ROCK1 | |
| SCHEMBL3759654 | 0.75 | EGFR (0.83) | WEE1ALKPDGFRAJAK2ROCK1 | |
| SCHEMBL3714937 | 0.73 | PDGFRA (1.00) | WEE1ALKPDGFRAJAK2ROCK1 | |
| SCHEMBL26395523 | 0.70 | PDGFRA (1.00) | WEE1ALKPDGFRAJAK2ROCK1 | |
| SCHEMBL16289834 | 0.69 | WEE1 (0.54) | WEE1ALKPDGFRAJAK2ROCK1 | |
| SCHEMBL29780520 | 0.69 | SYK (0.44) | ALKJAK2JAK3SYK | |
| SCHEMBL1395335 | 0.69 | SYK (0.44) | ALKJAK2JAK3SYK | |
| SCHEMBL24625516 | 0.68 | WEE1 (0.82) | WEE1ALKPDGFRAJAK2ROCK1 | |
| SCHEMBL14748407 | 0.67 | ROCK2 (0.50) | JAK2ROCK1DAPK3PRKD3MAP4K4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2435422-B1 | PYRIMIDINE INHIBITORS OF KINASE ACTIVITY | ABBVIE INC (US) | 2014-12-17 | — | — | EP | claimed |
| US-8486933-B2 | Pyrimidine inhibitors of kinase activity | ABBVIE INC. (US) | 2013-07-16 | — | — | US | claimed |
| WO-2010138578-A1 | PYRIMIDINE INHIBITORS OF KINASE ACTIVITY | ABBOTT LABORATORIES (US) | 2010-12-02 | — | — | WO | claimed |
| US-20100305112-A1 | PYRIMIDINE INHIBITORS OF KINASE ACTIVITY | ABBOTT LABORATORIES (US) | 2010-12-02 | — | — | US | claimed |
| EP-2435422-B1 | PYRIMIDINE INHIBITORS OF KINASE ACTIVITY | ABBVIE INC (US) | 2014-12-17 | — | — | EP | disclosed |
| US-8486933-B2 | Pyrimidine inhibitors of kinase activity | ABBVIE INC. (US) | 2013-07-16 | — | — | US | disclosed |
| WO-2010138578-A1 | PYRIMIDINE INHIBITORS OF KINASE ACTIVITY | ABBOTT LABORATORIES (US) | 2010-12-02 | — | — | WO | disclosed |
| US-20100305112-A1 | PYRIMIDINE INHIBITORS OF KINASE ACTIVITY | ABBOTT LABORATORIES (US) | 2010-12-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100305112-A1 | PYRIMIDINE INHIBITORS OF KINASE ACTIVITY | IGF1R, TK1, CDK2 | WEE1 195/4885ALK 397/4885PDGFRA 210/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.